{"nctId":"NCT05780424","briefTitle":"BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)","startDateStruct":{"date":"2020-12-16","type":"ACTUAL"},"conditions":["COVID-19"],"count":353,"armGroups":[{"label":"BRII-196/BRII-198 plus SOC","type":"EXPERIMENTAL","interventionNames":["Biological: BRII-196","Biological: BRII-198","Biological: Remdesivir"]},{"label":"Placebo plus SOC","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo","Biological: Remdesivir"]}],"interventions":[{"name":"BRII-196","otherNames":[]},{"name":"BRII-198","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Remdesivir","otherNames":["Veklury"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Refer to the master protocol (NCT04501978)\n\nExclusion Criteria:\n\n* Refer to the master protocol (NCT04501978)\n* Additional Exclusion Criteria:\n\n  * Pregnant women\n  * Nursing mothers\n* In addition, prior to the initial futility assessment which is performed when approximately 150 participants have been enrolled on BRII-196/BRII-198 and 150 on placebo, patients on high-flow oxygen or non-invasive ventilation (category 5 of the pulmonary ordinal outcome) will be excluded. These patients may be eligible for the trial if the initial futility assessment is passed by this agent.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With an Ordinal Outcome on Day 5","description":"Ordinal outcome with 7 mutually exclusive categories","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"14","spread":null}]},{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"20","spread":null}]},{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"42","spread":null}]},{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"57","spread":null}]},{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Died From All Causes","description":"All-cause mortality","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Safety Outcome Through Day 5","description":"Death, SAE, clinical organ failure, serious infections, or Grade 3 or 4 event through Day 5","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Safety Outcome Through Day 28","description":"Death, SAE, clinical organ failure, serious infections, or Grade 3 or 4 event through Day 28","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Safety Outcome Through Day 90","description":"Death, SAE, clinical organ failure, serious infections through Day 90","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":176},"commonTop":["Dyspnea","Hypoxia","Hypotension","Fatigue","Cough"]}}}